We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+0.4%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$549M
AUM Growth
-$96.1M
Cap. Flow
-$15.7M
Cap. Flow %
-2.86%
Top 10 Hldgs %
73.13%
Holding
35
New
2
Increased
2
Reduced
22
Closed
2

Top Buys

Rank Stock Value
1
LITS
Lite Strategy Inc
LITS
+$34.4M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.51M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$2.01M
4
VSTM icon
Verastem
VSTM
+$1.17M

Top Sells

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$8.73M
2
LHDX
Lucira Health, Inc. Common Stock
LHDX
+$4.39M
3
EPZM
Epizyme, Inc
EPZM
+$2.15M
4
TECX
Tectonic Therapeutic
TECX
+$1.02M
5
CYTK icon
Cytokinetics
CYTK
+$580K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$118M 21.51%
7,648,268
– –
ITOS
2
DELISTED
iTeos Therapeutics
ITOS
$85.9M 15.66%
1,844,727
-262,365
-12% -$8.73M
RPTX
3
DELISTED
Repare Therapeutics
RPTX
$34.6M 6.3%
1,639,849
– –
LITS
4
Lite Strategy Inc
LITS
$33.4M
$33M 6.01%
+617,549
New +$34.4M
MRUS
5
DELISTED
Merus
MRUS
$29.5M 5.38%
927,302
-14,646
-2% -$414K
HOWL icon
6
Werewolf Therapeutics
HOWL
$45.8M
$28.4M 5.19%
2,388,011
– –
HARP
7
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$24.1M 4.4%
319,671
– –
NTLA icon
8
Intellia Therapeutics
NTLA
$1.8B
$19M 3.46%
160,527
-2,093
-1% -$262K
TCRR
9
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$15.7M 2.86%
3,370,982
– –
TPTX
10
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$12.9M 2.36%
271,350
– –
ONCR
11
DELISTED
Oncorus, Inc.
ONCR
$12.5M 2.28%
2,377,031
– –
CRNX icon
12
Crinetics Pharmaceuticals
CRNX
$9B
$10.8M 1.97%
379,792
+81,400
+27% +$2.01M
CYTK icon
13
Cytokinetics
CYTK
$10B
$10.6M 1.93%
232,268
-15,023
-6% -$580K
EPIX
14
DELISTED
ESSA Pharma
EPIX
$9.49M 1.73%
668,688
-14,599
-2% -$163K
BCRX icon
15
BioCryst Pharmaceuticals
BCRX
$2.51B
$9.17M 1.67%
661,951
-42,816
-6% -$567K
TVTX icon
16
Travere Therapeutics
TVTX
$6.19B
$8.94M 1.63%
287,893
-18,622
-6% -$524K
GTHX
17
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$8.75M 1.59%
856,798
-3,704
-0.4% -$47.2K
EPZM
18
DELISTED
Epizyme, Inc
EPZM
$8.56M 1.56%
3,425,202
-547,628
-14% -$2.15M
YMAB
19
DELISTED
Y-mAbs Therapeutics
YMAB
$7.24M 1.32%
446,457
-6,513
-1% -$139K
GERN icon
20
Geron
GERN
$970M
$6.86M 1.25%
5,623,889
-108,881
-2% -$156K
ADCT icon
21
ADC Therapeutics
ADCT
$146M
$6.82M 1.24%
337,396
-7,123
-2% -$172K
VSTM icon
22
Verastem
VSTM
$654M
$6.71M 1.22%
272,628
+37,223
+16% +$1.17M
HRMY icon
23
Harmony Biosciences
HRMY
$2.28B
$6.07M 1.11%
142,437
-9,213
-6% -$367K
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
$5.93M 1.08%
513,333
-33,225
-6% -$370K
NEO icon
25
NeoGenomics
NEO
$2.32B
$4.79M 0.87%
140,422
-9,082
-6% -$356K
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q4 2021 Portfolio in Review

As of Q4 2021, MPM BioImpact held 35 positions worth $549M, down 15% from $645M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

MPM BioImpact's Q4 2021 filing shows 2 new, 2 increased, 22 reduced and 2 closed positions. Its largest new stake was Lite Strategy Inc: 617,549 shares worth $33M. The largest sale was iTeos Therapeutics, an estimated $8.73M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

  • MPM BioImpact's largest Q4 2021 buy was Lite Strategy Inc: 617,549 shares worth $33M.
  • MPM BioImpact added most to Crinetics Pharmaceuticals in Q4 2021, an estimated $2.01M increase.
  • MPM BioImpact's biggest Q4 2021 reduction was iTeos Therapeutics, cutting an estimated $8.73M.
  • MPM BioImpact fully exited Lucira Health, Inc. Common Stock in Q4 2021, selling an estimated $4.39M.
  • MPM BioImpact's ten largest holdings make up 73% of its $549M portfolio in Q4 2021.
  • MPM BioImpact opened 2 new positions and closed 2 in Q4 2021.
  • MPM BioImpact's portfolio value fell 15% quarter-over-quarter to $549M.

Based on MPM BioImpact's 13F filing for Q4 2021, filed 11 Feb 2022.